NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Short Interest Update

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) was the target of a significant growth in short interest in February. As of February 13th, there was short interest totaling 106,574 shares, a growth of 21.1% from the January 29th total of 88,032 shares. Approximately 2.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 45,479 shares, the days-to-cover ratio is presently 2.3 days. Based on an average daily trading volume, of 45,479 shares, the days-to-cover ratio is presently 2.3 days. Approximately 2.8% of the shares of the stock are sold short.

NLS Pharmaceutics Price Performance

Shares of NLS Pharmaceutics stock opened at $2.82 on Friday. The business has a 50 day simple moving average of $2.57 and a two-hundred day simple moving average of $9.28. NLS Pharmaceutics has a 12 month low of $1.89 and a 12 month high of $30.80.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of NLS Pharmaceutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

About NLS Pharmaceutics

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.